ML 161

Research use only, not for human use.

Inhibitor of protease-activated receptor 1 (PAR1)-mediated platelet activation (IC50 = 0.26 μM for the inhibition of platelet P-selectin expression on human platelets).

Inhibitor of protease-activated receptor 1 (PAR1)-mediated platelet activation (IC50 = 0.26 μM for the inhibition of platelet P-selectin expression on human platelets). Thought to act allosterically. Also inhibits thrombin-induced platelet activation.

Parmodulin 2 (ML161; 10 μM; for 30 minutes) inhibits proinflammatory signaling in endothelial HUVECs cells.

Parmodulin 2 (ML161; 5 mg/kg; IV) significantly inhibits platelet thrombus formation, with a 73% inhibition in AUC (area under the curve). Parmodulin 2 inhibits platelet thrombus formation in vivo, and it does not prolong bleeding time. Parmodulin 2 selectively inhibits platelet aggregation through Par1 and the α2A-adrenergic receptor. Animal Model:C57BL/6J wild type mice Dosage:5 mg/kg (Pharmacokinetic Analysis)Administration:IV Result:Significantly inhibited platelet thrombus formation, with a 73% inhibition in AUC.

AG-670 | CID-1048267

GPCR/G Protein

PAR

PAR-1

Other Indications

——

423735-93-7

361.23

C17H17BrN2O2

>98% (HPLC)

DMSO: 72 mg/mL (199.31 mM)

O=C(NC1=CC=CC(NC(CCC)=O)=C1)C2=CC=CC=C2Br

2-bromo-N-[3-[(1-oxobutyl)amino]phenyl]-benzamide

(-20℃)

With Ice Pack

≥ 2 years